Monday, August 21, 2017 6:33:38 PM
(1) On 8/5/2016 Don Dickson invests $70,000 in a Private Placement offering of convertible notes and warrants.
(2) On 10/13/2016 Don Dickson converts his note into common stock.
(3) On 4/17/2017 Dr. Eric Bunting invests $50,000 in a Private Placement offering of convertible notes and warrants.
(4) On 5/15/17 Richard Munn invests $10,000 in a Private Placement offering of convertible notes and warrants. He immediately convert the notes to common stock.
(5) On 5/15/2017 Richard Munn buys 42,000 shares of common stock in the open market at $0.24 per share.
(6) On 5/31/2017 Thomas Bundros invests $100,000 in a private Placement of convertible notes and warrants. He immediately converts the notes to common stock.
(7) On 7/19/2017 Dr. Eric Bunting invests an additional $40,000 to convert his warrants and stock options into common stock well before their expiration dates.
(8) On 7/30/2017 Don Dickson invests an additional $38,500 to convert warrants into common stock.
(9) On 8/2/2017 Gary Buchler invests $50,000 to buy common stock at market prices and convert all of his vested stock options.
All of the individuals named above are part of QSEP's Board of Directors. All of them are investing their own money in QSEP. While NDA's may prevent them from talking about the specifics of any particular corporate relationships, this is a powerful alternative way to express just how confident they are in QSEP's immediate future.
I've emphasized the word immediate because I think the motivation for early conversion of 10 year stock options is based on a strong belief that the stock will be going substantially higher in the near term. This early conversion will reduce the future tax burden substantially if that were to occur (long term capital gain instead of ordinary income).
Recent QSEP News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 08:39:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/05/2023 01:05:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 11:52:03 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM